Literature DB >> 33742325

Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease.

Alejandro Horga1,2,3, Andreea Manole4,5, Alice L Mitchell6, Enrico Bugiardini4,7, Iain P Hargreaves8, Walied Mowafi9, Conceição Bettencourt10, Emma L Blakely11, Langping He11, James M Polke12, Catherine E Woodward12, Ilaria Dalla Rosa6, Sachit Shah13, Alan M Pittman5, Ros Quinlivan4,7, Mary M Reilly4,7, Robert W Taylor11, Ian J Holt6,14,15, Michael G Hanna4,7, Robert D S Pitceathly4,7, Antonella Spinazzola4,6, Henry Houlden16,17,18.   

Abstract

Mutations in nuclear-encoded protein subunits of the mitochondrial ribosome are an increasingly recognised cause of oxidative phosphorylation system (OXPHOS) disorders. Among them, mutations in the MRPL44 gene, encoding a structural protein of the large subunit of the mitochondrial ribosome, have been identified in four patients with OXPHOS defects and early-onset hypertrophic cardiomyopathy with or without additional clinical features. A 23-year-old individual with cardiac and skeletal myopathy, neurological involvement, and combined deficiency of OXPHOS complexes in skeletal muscle was clinically and genetically investigated. Analysis of whole-exome sequencing data revealed a homozygous mutation in MRPL44 (c.467 T > G), which was not present in the biological father, and a region of homozygosity involving most of chromosome 2, raising the possibility of uniparental disomy. Short-tandem repeat and genome-wide SNP microarray analyses of the family trio confirmed complete maternal uniparental isodisomy of chromosome 2. Mitochondrial ribosome assembly and mitochondrial translation were assessed in patient derived-fibroblasts. These studies confirmed that c.467 T > G affects the stability or assembly of the large subunit of the mitochondrial ribosome, leading to impaired mitochondrial protein synthesis and decreased levels of multiple OXPHOS components. This study provides evidence of complete maternal uniparental isodisomy of chromosome 2 in a patient with MRPL44-related disease, and confirms that MRLP44 mutations cause a mitochondrial translation defect that may present as a multisystem disorder with neurological involvement.

Entities:  

Keywords:  MRPL44; Mitochondrial disease; Oxidative phosphorylation; Uniparental disomy; Whole-exome sequencing

Mesh:

Substances:

Year:  2021        PMID: 33742325     DOI: 10.1007/s11033-021-06188-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

1.  Mutation in mitochondrial ribosomal protein MRPS22 leads to Cornelia de Lange-like phenotype, brain abnormalities and hypertrophic cardiomyopathy.

Authors:  Paulien Smits; Ann Saada; Saskia B Wortmann; Angelien J Heister; Maaike Brink; Rolph Pfundt; Chaya Miller; Dorothea Haas; Ralph Hantschmann; Richard J T Rodenburg; Jan A M Smeitink; Lambert P van den Heuvel
Journal:  Eur J Hum Genet       Date:  2010-12-29       Impact factor: 4.246

2.  Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation.

Authors:  Chaya Miller; Ann Saada; Nava Shaul; Naama Shabtai; Efrat Ben-Shalom; Avraham Shaag; Eli Hershkovitz; Orly Elpeleg
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

3.  MRPS22 mutation causes fatal neonatal lactic acidosis with brain and heart abnormalities.

Authors:  Fabian Baertling; Tobias B Haack; Richard J Rodenburg; Jörg Schaper; Annette Seibt; Tim M Strom; Thomas Meitinger; Ertan Mayatepek; Berit Hadzik; Gündüz Selcan; Holger Prokisch; Felix Distelmaier
Journal:  Neurogenetics       Date:  2015-02-10       Impact factor: 2.660

4.  Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy.

Authors:  Louise Galmiche; Valérie Serre; Marine Beinat; Zahra Assouline; Anne-Sophie Lebre; Dominique Chretien; Patrick Nietschke; Vladimir Benes; Nathalie Boddaert; Daniel Sidi; Francis Brunelle; Marlène Rio; Arnold Munnich; Agnès Rötig
Journal:  Hum Mutat       Date:  2011-09-14       Impact factor: 4.878

5.  Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation.

Authors:  A Saada; A Shaag; S Arnon; T Dolfin; C Miller; D Fuchs-Telem; A Lombes; O Elpeleg
Journal:  J Med Genet       Date:  2007-09-14       Impact factor: 6.318

6.  Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy.

Authors:  Christopher J Carroll; Pirjo Isohanni; Rosanna Pöyhönen; Liliya Euro; Uwe Richter; Virginia Brilhante; Alexandra Götz; Taina Lahtinen; Anders Paetau; Helena Pihko; Brendan J Battersby; Henna Tyynismaa; Anu Suomalainen
Journal:  J Med Genet       Date:  2013-01-12       Impact factor: 6.318

7.  Ribosome. The structure of the human mitochondrial ribosome.

Authors:  Alexey Amunts; Alan Brown; Jaan Toots; Sjors H W Scheres; V Ramakrishnan
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

8.  Human mitochondrial ribosomes can switch their structural RNA composition.

Authors:  Joanna Rorbach; Fei Gao; Christopher A Powell; Aaron D'Souza; Robert N Lightowlers; Michal Minczuk; Zofia M Chrzanowska-Lightowlers
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-11       Impact factor: 11.205

Review 9.  Mitochondria: impaired mitochondrial translation in human disease.

Authors:  Veronika Boczonadi; Rita Horvath
Journal:  Int J Biochem Cell Biol       Date:  2014-01-08       Impact factor: 5.085

Review 10.  Mitochondrial diseases: translation matters.

Authors:  Sarah Pearce; Catherine Laura Nezich; Antonella Spinazzola
Journal:  Mol Cell Neurosci       Date:  2012-09-07       Impact factor: 4.314

View more
  1 in total

1.  Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect.

Authors:  Marisa W Friederich; Gabrielle C Geddes; Saskia B Wortmann; Ann Punnoose; Eric Wartchow; Kaz M Knight; Holger Prokisch; Geralyn Creadon-Swindell; Johannes A Mayr; Johan L K Van Hove
Journal:  Mol Genet Metab       Date:  2021-06-10       Impact factor: 4.204

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.